| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
|---|---|---|---|---|
| 1 15 letter or more gain in visual acuity (ETDRS Chart) | 2 | Risk Ratio (M-H, Fixed, 95% CI) | Totals not selected | |
| 1.1 Ranibizumab 0.3 mg | 1 | Risk Ratio (M-H, Fixed, 95% CI) | Not estimable | |
| 1.2 Ranibizumab 0.5 mg | 1 | Risk Ratio (M-H, Fixed, 95% CI) | Not estimable | |
| 1.3 Pegaptanib sodium 0.3 mg | 1 | Risk Ratio (M-H, Fixed, 95% CI) | Not estimable | |
| 1.4 Pegaptanib sodium 1.0 mg | 1 | Risk Ratio (M-H, Fixed, 95% CI) | Not estimable |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.